Q-omics provides the consensus-scored TRABD2B profile across patient tissues and cancer cell-line models. TRABD2B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TRABD2B is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, TRABD2B RNA expression shows 15,898 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, BLCA, and THYM as cancer lineages where TRABD2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRABD2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRABD2B survival associations across molecular data types. TRABD2B RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRABD2B RNA expression–survival associations across cancer types. High TRABD2B expression shows unfavorable associations in UVM, OV and MESO, but favorable associations in ESCA, BRCA and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TRABD2B RNA expression.
This table summarizes TRABD2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRABD2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRABD2B shows lower tumor expression in BLCA, KICH, LUSC, BRCA and COAD and higher tumor expression in KIRC. The BLCA box plot shows higher TRABD2B RNA expression in normal versus tumor tissue (log2 FC = −2.180, t-test p < 0.001).
This table shows molecular features associated with TRABD2B in patient tissues and cancer cell lines. In patient samples, TRABD2B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRABD2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SKIN.
